

ACCELERATED DISTRIBUTION DEMONSTRATION SYSTEM

REGULATORY INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR: 9107300295	DOC. DATE: 91/07/23	NOTARIZED: NO	DOCKET #
FACIL: 50-269	Oconee Nuclear Station, Unit 1,	Duke Power Co.	05000269
50-270	Oconee Nuclear Station, Unit 2,	Duke Power Co.	05000270
50-287	Oconee Nuclear Station, Unit 3,	Duke Power Co.	05000287
50-369	William B. McGuire Nuclear Station, Unit 1,	Duke Powe	05000369
50-370	William B. McGuire Nuclear Station, Unit 2,	Duke Powe	05000370
50-413	Catawba Nuclear Station, Unit 1,	Duke Power Co.	05000413
50-414	Catawba Nuclear Station, Unit 2,	Duke Power Co.	05000414
AUTH. NAME	AUTHOR AFFILIATION		
TUCKMAN, M.S.	Duke Power Co.		
RECIP. NAME	RECIPIENT AFFILIATION		
	Document Control Branch (Document Control Desk)		

SUBJECT: Forwards rept of false negative blind urine drug screen. Analysis correctly identified marijuana but did not confirm presence of cocaine. Repeat analysis correctly identified cocaine. Procedures implemented to prevent recurrence.

DISTRIBUTION CODE: A022D COPIES RECEIVED: LTR 1 ENCL 1 SIZE: 4
 TITLE: Fitness for Duty Program: Blind Performance Test/Other

NOTES: LPDR 2cys AMDTS to FSAR. ASLB 1cy. 05000413
~~LPDR 2cys AMDTS to FSAR. ASLB 1cy.~~ 05000414

	RECIPIENT ID CODE/NAME	COPIES	LTTR	ENCL	RECIPIENT ID CODE/NAME	COPIES	LTTR	ENCL
	PD2-3 LA	1	1		PD2-3 PD	1	1	
	WIENS, L	1	1		REED, T	1	1	
	MARTIN, R	1	1					
INTERNAL:	ACRS	1	1		NRR/DRIS/RSGB	1	1	
	NUDOCS-ABSTRACT	1	1		<u>REG FILE 01</u>	1	1	
	RGN2 . 02	1	1					
EXTERNAL:	NRC PDR	1	1		NSIC	1	1	
NOTES:		3	3					

NOTE TO ALL "RIDS" RECIPIENTS:

PLEASE HELP US TO REDUCE WASTE! CONTACT THE DOCUMENT CONTROL DESK, ROOM P1-37 (EXT. 20079) TO ELIMINATE YOUR NAME FROM DISTRIBUTION LISTS FOR DOCUMENTS YOU DON'T NEED!

TOTAL NUMBER OF COPIES REQUIRED: LTTR 15 ENCL 15

MA-4

July 23, 1991

U. S. Nuclear Regulatory Commission
Attention: Document Control Desk
Washington, D. C. 20555

Subject: Fitness for Duty Program
Oconee Nuclear Station; Docket Nos. 50-269, -270, -287
McGuire Nuclear Station, Docket Nos. 50-369, -370
Catawba Nuclear Station, Docket Nos. 50-413, -414

Gentlemen:

Pursuant to 10 CFR 26 Appendix 2, Subpart B 2.8(e)(4), we are hereby transmitting information concerning an unsatisfactory performance testing result.

Very truly yours,

M. S. Tuckman
M. S. Tuckman

JAR/03
Attachments

xc: Mr. S. D. Ebnetter
Region II Administrator, USNRC

USNRC Project Managers, Duke Stations

USNRC Resident Inspectors, Duke Stations

7107300295 910723
PDR ADOCK 05000269
V PDR

A022
11

Document Control Desk

July 23, 1991

Page 2

bxc: W. E. Dukes WC08C
S. P. Murdock PB04B
J. W. Wells-CNS
E. M. Rogers-ONS
I. R. Crawford PB04B
R. M. Bisanar PB05E
GS 801.01

June 24, 1991

Subject: False Negative Blind Urine Drug Screen

A blind urine specimen, Requisition #303826 was submitted by Duke Power from Catawba Nuclear Station to SmithKline Beecham Laboratory in Atlanta on May 24, 1991. The blind specimen contained both cocaine and marijuana metabolites at the concentration of 450 ng/ml and 150 ng/ml respectively. The specimen was reported to Duke Power on May 28, 1991 as positive for marijuana at the 100 ng/ml and 50 ng/ml cut off level. However, it was reported as negative for cocaine.

Dr. McHan notified the laboratory of the result and asked them to investigate the error and repeat the specimen on June 13, 1991. Ben R. Wells, Technical Manager of the SmithKline Beecham Laboratory contacted my office that day. I returned his call the next day and he informed me of the result and that repeat of the test was positive for cocaine. Dr. McHan notified me of the result, also.

Mr. Wells stated that the specimen tested positive on the original (EMIT) screening, but that it did not confirm on the GC-MS methodology.

There was not a sample mix up and he believes the negative report "is attributable to a random occurrence in the extraction process". Please see the enclosed letter of investigation and report. He has assured me that any specimens that are positive for marijuana or cocaine on EMIT, but do not confirm on GC-MS, will be scrutinized closer in the future and procedures have been implemented.

In summary, a blind specimen contained marijuana and cocaine was submitted. Marijuana was identified correctly. Cocaine was identified on the EMIT test, but did not confirm on GC-MS. Repeat analysis correctly identified cocaine. Procedures have been implemented to prevent the recurrence of this error.

W. E. Dukes, Jr., MD

W. E. Dukes, Jr., MD
Corporate Medical Director



SmithKline Beecham
Clinical Laboratories

JUNE 20, 1991

W. E. DUKES, JR., M.D.
422 S. CHURCH STREET
CHARLOTTE, NC 28201-1007

SUBJECT: FALSE NEGATIVE BLIND RESULT

DEAR DR. DUKES,

I AM WRITING TO INFORM YOU OF A FALSE NEGATIVE RESULT ON A BLIND SAMPLE (REQ.# 3038286) SUBMITTED BY YOU ON MAY 25, 1991. THE SAMPLE HAS BEEN REANALYZED AND FOUND TO BE POSITIVE FOR BENZOYLECGONINE. THE ORIGINAL SCREENING TEST DID INDICATE A PRESUMPTIVE POSITIVE FOR BENZOYLECGONINE. HOWEVER, THE SUBSEQUENT CONFIRMATION TEST DID NOT CONFIRM THE PRESENCE OF THAT COMPOUND. THUS, THE REPORT YOU RECEIVED STATED THAT THE SPECIMEN WAS NEGATIVE FOR COCAINE. UPON REANALYSIS, THE PRESENCE OF BENZOYLECGONINE WAS CONFIRMED IN THE SAMPLE.

OUR REVIEW OF THE ADDITIONAL SAMPLES, CONTROLS, AND IN-HOUSE BLINDS ON THE INITIAL RUN DOES NOT INDICATE THAT SPECIMEN INTEGRITY WAS BREACHED IN ANY FASHION. WE BELIEVE THE INITIAL NEGATIVE REPORT IS ATTRIBUTABLE TO A RANDOM OCCURRENCE IN THE EXTRACTION PROCESS. PLEASE BE ASSURED THAT PROCEDURES HAVE BEEN INSTITUTED TO PREVENT SUCH AN OCCURRENCE IN THE FUTURE.

WE APPRECIATE THE OPPORTUNITY TO BE OF SERVICE AND APOLOGIZE FOR ANY INCONVENIENCE. THANK YOU FOR CONTACTING SMITHKLINE BEECHAM CLINICAL LABORATORIES, AND PLEASE DO NOT HESITATE TO CALL ME IF I CAN BE OF FURTHER ASSISTANCE.

SINCERELY,

BEN R. WELLS
TECHNICAL MANAGER